Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 04, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in their interests in the company's Ordinary Shares and American Depository Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure regarding director share allocations and does not contain financial performance data.
Material Changes
The material change reported is the provisional allocation of share awards to Non-Executive Directors on December 31, 2005, resulting from the annual reinvestment of dividends paid throughout 2005. These allocations were confirmed to the company and directors on January 3, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a compliance notification under Disclosure Rule 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Type: Annual dividend reinvestment awards allocated to Non-Executive Directors.
- Allocation Date: December 31, 2005 (provisional); confirmed January 3, 2006.
- Share Prices: Allocations were made at an average price of GBP 14.73 for Ordinary Shares and USD 50.76 for ADSs.
- Directors Involved: Includes Sir Ian Prosser, Dr Lucy Shapiro, Sir Christopher Gent, Mr Lawrence Culp, Mr Crispin Davis, Sir Deryck Maughan, Dr Ronaldo Schmitz, and Sir Robert Wilson.
- Financial Data: No financial performance metrics are included in this specific filing.